Ocular Therapeutix shared its third-quarter results, highlighting progress on its product Xpaxly for wet AMD treatment.

Nov 9, 2026, 9:20 AM ETResultsRead the original at Benzinga

Good for OCUL

Ocular Therapeutix reported successful Phase 3 results for Xpaxly and plans to seek approval in Q4 2026. Its $530.6 million cash supports work into 2028, but Xpaxly is not approved and launch costs are excluded.

OCUL · Ocular Therapeutix

AI read · Good for OCUL

The AI's read

That result gives the company a stronger case for seeking approval and moves its main drug closer to a possible launch. The company still needs regulators to accept the application, and its stated cash runway leaves out launch spending.

Get alerts for OCUL

Follow Ocular Therapeutix (OCUL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for OCUL

Free on the App Store and Google Play, or on the web.